Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01751438 · ClinicalTrials.gov registry record · Phase 2
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
A Phase 2 study of Prostate Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 4
- Study locations
NCT01751438: Completed Phase 2 study of Prostate Cancer, sponsored by M.D. Anderson Cancer Center.
NCT01751438 is a Phase 2 study of Prostate Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 180 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (70% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01751438, a Phase 2 study of Prostate Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical research study is to learn if treatment with standard systemic therapy (androgen deprivation therapy or bilateral orchiectomy) in combination with surgery or radiation therapy is more effective at controlling prostate cancer than standard systemic therapy alone. The safety of this treatment combination will also be studied.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaires
- OTHER Best Systemic Therapy (BST)
- OTHER Best Systemic Therapy (BST) + Surgery or Radiation Therapy
- OTHER Phone Call/Email
Study Locations (4)
California
- UCSF University of California - San Francisco
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- University of Texas MD Anderson Cancer Center - Houston
British Columbia
- Vancouver Prostate Center - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2013-03-18 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01751438
The ClinicalTrials.gov registry entry for NCT01751438 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (70% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Questionnaires is the first listed.
NCT01751438 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT01751438 about?
NCT01751438 is a clinical study titled "Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)". The goal of this clinical research study is to learn if treatment with standard systemic therapy (androgen deprivation therapy or bilateral orchiectomy) in combination with surgery or radiation therapy is more effective at controlling prostate cancer than standard systemic therapy alone. The safety ...
What is the current status of trial NCT01751438?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2013-03-18. Estimated completion is 2023-04-19.
What conditions does trial NCT01751438 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01751438?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Best Systemic Therapy (BST) (OTHER), Best Systemic Therapy (BST) + Surgery or Radiation Therapy (OTHER), Phone Call/Email (OTHER).
Who is sponsoring clinical trial NCT01751438?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01751438 being conducted?
This trial has 4 study locations across California, Pennsylvania, Texas, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.